| Literature DB >> 30955224 |
Jean Bousquet1,2,3,4,5,6, Oliver Pfaar7, Alkis Togias8, Holger J Schünemann9, Ignacio Ansotegui10, Nikolaos G Papadopoulos11,12, Ioanna Tsiligianni13, Ioana Agache14, Josep M Anto15,16,17,18, Claus Bachert19, Anna Bedbrook1, Karl-Christian Bergmann20, Sinthia Bosnic-Anticevich21, Isabelle Bosse22, Jan Brozek9, Moises A Calderon23, Giorgio W Canonica24, Luigi Caraballo25,26, Victoria Cardona27, Thomas Casale28, Lorenzo Cecchi29, Derek Chu9, Elisio Costa30, Alvaro A Cruz31,32, Wienczyslawa Czarlewski33, Stephen R Durham34, George Du Toit35, Mark Dykewicz36, Motohiro Ebisawa37, Jean Luc Fauquert38, Montserrat Fernandez-Rivas39, Wytske J Fokkens40, João Fonseca41,42, Jean-François Fontaine43, Roy Gerth van Wijk44, Tari Haahtela45, Susanne Halken46, Peter W Hellings47,48, Despo Ierodiakonou13, Tomohisa Iinuma49, Juan Carlos Ivancevich50, Lars Jacobsen51, Marek Jutel52, Igor Kaidashev53, Musa Khaitov54, Omer Kalayci55, Jörg Kleine Tebbe56, Ludger Klimek57, Marek L Kowalski58,59, Piotr Kuna60, Violeta Kvedariene61,62, Stefania La Grutta63, Désirée Larenas-Linemann64, Susanne Lau65, Daniel Laune66, Lan Le67, Karin Lodrup Carlsen68,69, Olga Lourenço70, Hans-Jørgen Malling71, Gert Marien4, Enrica Menditto72, Gregoire Mercier73, Joaquim Mullol74,75, Antonella Muraro76, Robyn O'Hehir77, Yoshitaka Okamoto49, Giovanni B Pajno78, Hae-Sim Park79, Petr Panzner80, Giovanni Passalacqua81, Nhan Pham-Thi82, Graham Roberts83, Ruby Pawankar84, Christine Rolland85, Nelson Rosario86, Dermot Ryan87, Bolesław Samolinski88, Mario Sanchez-Borges89, Glenis Scadding90, Mohamed H Shamji91,92, Aziz Sheikh93, Gunter J Sturm94,95, Ana Todo Bom96, Sanna Toppila-Salmi45, Maryline Valentin-Rostan97, Arunas Valiulis98,99,100, Erkka Valovirta101, Maria-Teresa Ventura102, Ulrich Wahn103, Samantha Walker104, Dana Wallace105, Susan Waserman106, Arzu Yorgancioglu107, Torsten Zuberbier20.
Abstract
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients.Entities:
Keywords: allergen immunotherapy; asthma; children; mHealth; rhinitis; stratification
Mesh：
Substances：
Year: 2019 PMID： 30955224 DOI： 10.1111/all.13805
Source DB: PubMed Journal: Allergy ISSN： 0105-4538 Impact factor: 13.146